<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72172">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01888042</url>
  </required_header>
  <id_info>
    <org_study_id>2011-00979-14</org_study_id>
    <secondary_id>2011/1733</secondary_id>
    <nct_id>NCT01888042</nct_id>
  </id_info>
  <brief_title>Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer</brief_title>
  <acronym>POORTOR</acronym>
  <official_title>Phase II Study Assessing Everolimus as Fist Line Treatment in Patients With Metstatic Kidney Cancer of Bad Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a an open label, multicentric, phase II study assessing the efficacy of everolimus
      (given per os) as a first line treatment in kidney cancer of bad prognosis.

      90 patients will be included (anticipated). The treatment by everolimus will continue until
      progression, significant toxicity or withdraw of consent
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From inclusion to progression, significant toxicity  or death wichever come first up to 56 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>From inclusion to progression, significant toxicity or death whichever come first up to 56 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response rate based on RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of Everolimus</measure>
    <time_frame>From inclusion to progression, significant toxicity or death whichever come first up to 56 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From inclusion to progression, significant toxicity or death whichever come first up to 56 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus will be administred per os every day at the same hour immediatly after a meal with a glass of water 10 mg (1 tablet of 10 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10 mg (1 tablet of 10 mg)</description>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Metastatic kidney cancer, regardless of histology (except Bellini carcinomas), with
             measurable or evaluable disease

          2. Age &gt;= 18 years

          3. With Karnofsky ≥ 60

          4. Without prior treatment for metastatic cancer (chemotherapy, targeted therapy, or
             mTOR inhibitor)

          5. Bad prognosis, defined as follows: at least three of the following six criteria of
             poor prognosis:

               -  Karnofski &lt;80

               -  LDH&gt; 1.5 ULN

               -  hemoglobin &lt;LLN

               -  corrected calcium&gt; 2.5 mmol / l (10 mg / dl)

               -  Time frame between initial diagnostic and treatment &lt;1 year

               -  More than one metastatic site

          6. medullary function: neutrophils ≥ 1.5 x 109 / L, Platelets ≥ 100 x 109 / L, Hb&gt; 8g/dL

          7. Hepatic function: bilirubin: ≤ 1.5 x ULN, ALT and AST ≤ 2.5x ULN in the absence of
             hepatic metastasis ≤ 5x ULN if hepatic metastasis documented

          8. Renal function: creatinine &lt;1.5 x ULN

          9. Life expectancy&gt; 3 months,

         10. Patient signed informed consent and agreeing to comply with the requirements of the
             trial

        Exclusion Criteria:

          1. Previous treatment with chemotherapy, targeted therapy, or mTOR inhibitor

          2. Previous radiotherapy in the last 2 weeks

          3. Chronic treatment with corticoids or immunosuppressive agents except substitutive
             opotherap.. A washout period of at least 8 days must be respected before the patient
             inclusion.

          4. Patients with brain metastases untreated or uncontrolled by prior treatment. The
             non-progression of the metastases must be proved by comparing two brain scans
             separated by a minimum interval of 6 weeks.

          5. Active bleeding

          6. Patient with positive serology HBs (Ag HBs (+) and AC anti-HBc (+)

          7. Hypersensitivity to everolimus, sirolimus, to other rapamycin derivatives or to any
             of the excipients

          8. Severe or uncontrolled medical pathology:

               -  unstable angor, symptomatic heart failure, myocardial infarction ≤ 6 months
                  before randomization, severe rhythm disorder,

               -  Uncontrolled diabetes with glycaemia&gt; 1.5X ULN.

               -  Active or uncontrolled infection.

               -  cirrhosis or chronic active hepatitis,

               -  severe alteration in lung function (&gt; 50% decrease in FEV or vital capacity)

          9. Other cancer within the past 3 years, with the exception of basal cell carcinoma and
             carcinoma in situ of the cervix

         10. Pregnant or lactating woman, and adults refusing an effective contraceptive method

         11. Participation in another clinical trial with an investigational drug

         12. Refusal of the patient to comply with the rules of the clinical trial

         13. Person deprived of liberty or person under guardianship, inability to submit to
             medical treatment test for geographical, social or psychological reasons.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard ESCUDIER</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernard ESCUDIER, MD</last_name>
    <phone>0142115410</phone>
    <phone_ext>+33</phone_ext>
    <email>bernard.escudier@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie MAIROT</last_name>
    <phone>0142116643</phone>
    <phone_ext>+33</phone_ext>
    <email>valerie.mairot@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard ESCUDIER, MD</last_name>
      <phone>0142445410</phone>
      <phone_ext>+33</phone_ext>
      <email>bernard.escudier@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 25, 2013</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
